Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

The tumor suppressor p53 inhibits tumor growth primarily through its ability to induce apoptosis. Mutations in p53 occur in at least 50% of human tumors. We hypothesized that reactivation of mutant p53 in such tumors should trigger massive apoptosis and eliminate the tumor cells. To test this, we screened a library of low-molecular-weight compounds in order to identify compounds that can restore wild-type function to mutant p53. We found one compound capable of inducing apoptosis in human tumor cells through restoration of the transcriptional transactivation function to mutant p53. This molecule, named PRIMA-1, restored sequence-specific DNA binding and the active conformation to mutant p53 proteins in vitro and in living cells. PRIMA-1 rescued both DNA contact and structural p53 mutants. In vivo studies in mice revealed an antitumor effect with no apparent toxicity. This molecule may serve as a lead compound for the development of anticancer drugs targeting mutant p53.

[1]  D. Lane,et al.  Activation of the cryptic DNA binding function of mutant forms of p53. , 1993, Nucleic acids research.

[2]  A. Levine,et al.  Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. , 1994, Genes & development.

[3]  K. Magnússon,et al.  Mutant p53 detected in a majority of Burkitt lymphoma cell lines by monoclonal antibody PAb240. , 1991, Oncogene.

[4]  M. Lindström,et al.  Immunolocalization of human p14(ARF) to the granular component of the interphase nucleolus. , 2000, Experimental cell research.

[5]  A. Neri,et al.  Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53. , 1995, Cancer research.

[6]  B. Groner,et al.  Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain , 1997, Nature Medicine.

[7]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[8]  C. Sherr,et al.  Tumor surveillance via the ARF-p53 pathway. , 1998, Genes & development.

[9]  C. Prives,et al.  Regulation of Mutant p53 Temperature-sensitive DNA Binding* , 1996, The Journal of Biological Chemistry.

[10]  K. Wiman,et al.  Reactivation of Mutant p53 through Interaction of a C-Terminal Peptide with the Core Domain , 1999, Molecular and Cellular Biology.

[11]  A. Fersht,et al.  Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy , 2000, Oncogene.

[12]  C. Prives,et al.  p53: puzzle and paradigm. , 1996, Genes & development.

[13]  M. Pincus,et al.  Conformational and Molecular Basis for Induction of Apoptosis by a p53 C-terminal Peptide in Human Cancer Cells* , 1999, The Journal of Biological Chemistry.

[14]  G. Selivanova,et al.  Reactivation of mutant p53: a new strategy for cancer therapy. , 1998, Seminars in Cancer Biology.

[15]  T. Halazonetis,et al.  Identification of an additional negative regulatory region for p53 sequence-specific DNA binding. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Giaccia,et al.  The complexity of p53 modulation: emerging patterns from divergent signals. , 1998, Genes & development.

[17]  Thierry Soussi,et al.  P53 Gene Mutation: Software and Database , 1996, Nucleic Acids Res..

[18]  J. Boeke,et al.  Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations , 1998, The EMBO journal.

[19]  D. Lane,et al.  Biochemical characterization of different conformational states of the Sf9 cell‐purified p53His175 mutant protein , 1999, FEBS letters.

[20]  G. Evan,et al.  A matter of life and cell death. , 1998, Science.

[21]  D. Lane,et al.  Regulation of the specific DNA binding function of p53 , 1992, Cell.

[22]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[23]  D. Lane,et al.  Allosteric Regulation of the Thermostability and DNA Binding Activity of Human p53 by Specific Interacting Proteins (*) , 1996, The Journal of Biological Chemistry.

[24]  D. Housman,et al.  p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.

[25]  A. Fersht,et al.  Mechanism of rescue of common p53 cancer mutations by second‐site suppressor mutations , 2000, The EMBO journal.

[26]  K. Kinzler,et al.  Disruption of p53 in human cancer cells alters the responses to therapeutic agents. , 1999, The Journal of clinical investigation.

[27]  K. Wiman,et al.  p53-induced apoptosis as a safeguard against cancer. , 1999, Biochemical and biophysical research communications.

[28]  K. Wiman,et al.  The single-stranded DNA end binding site of p53 coincides with the C-terminal regulatory region. , 1996, Nucleic acids research.

[29]  K. Wiman,et al.  Functional Rescue of Mutant p53 as a Strategy to Combat Cancer , 2002 .

[30]  T. Halazonetis,et al.  Structure–based rescue of common tumor–derived p53 mutants , 1996, Nature Medicine.

[31]  B. Foster,et al.  Pharmacological rescue of mutant p53 conformation and function. , 1999, Science.